Literature DB >> 8863485

Human astrocytoma cells (U-87 MG) exhibit a specific substance P binding site with the characteristics of an NK-1 receptor.

H Ogo1, N Kuroyanagi, A Inoue, H Nishio, Y Hirai, M Akiyama, D A DiMaggio, J E Krause, Y Nakata.   

Abstract

To investigate substance P (SP) receptors on an established human astrocytoma cell line (U-87 MG), [3H][Sar9,Met(O2)11]-SP, a selective SP receptor agonist, was used to identify and characterize the cell membrane binding sites for SP. SP receptor mRNA was examined by solution hybridization analysis, and the existence of SP binding protein on the surface of membranes was evaluated by flow cytometry using an anti-SP binding protein antibody. In U-87 MG and U-373 MG RNA preparations, transcripts were identified that corresponded to both mature and partially spliced receptor forms. In U-87 MG cell membrane-enriched preparations, the binding of [3H][Sar9,Met(O2)11]-SP was found to be time and cell number dependent, specific, saturable, and of high affinity. Equilibrium binding analysis revealed a single class of binding sites with an apparent KD of 1.15 +/- 0.15 nM and a Bmax of 108 +/- 9.8 fmol/mg of protein. [3H][Sar9, Met(O2)11]-SP binding was basically not influenced by addition of mono (Na+, Li+) or divalent (Mg2+, Mn2+, Ca2+) cations; only high doses of divalent cations decreased the binding. GTP and guanylyl-5'-imidodiphosphate, but not GDP and GMP, reduced the Bmax without changing the affinity of [3H][Sar9,Met(O2)11]-SP. We also examined the effects of pretreatment with three lectins [concanavalin A (con A), wheat germ agglutinin (WGA), and Lens culinaris agglutinin (LCA)] to determine the nature of carbohydrate chains on the U-87 MG cell. Of three lectins analyzed for effects on agonist binding, WGA and LCA had an inhibitory effect, whereas con A was ineffective. These results suggest that SP receptors on the human astrocytoma cell line U-87 MG have either a biantennary complex-type or a high mannose-type of carbohydrate chain and may be regulated by GTP-binding protein(s).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863485     DOI: 10.1046/j.1471-4159.1996.67051813.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition.

Authors:  Yi-Xin Zhang; Xiao-Fang Li; Guo-Qiang Yuan; Hui Hu; Xiao-Yun Song; Jing-Yi Li; Xiao-Kang Miao; Tian-Xiong Zhou; Wen-Le Yang; Xiao-Wei Zhang; Ling-Yun Mou; Rui Wang
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

2.  Neurokinin-1 receptor directly mediates glioma cell migration by up-regulation of matrix metalloproteinase-2 (MMP-2) and membrane type 1-matrix metalloproteinase (MT1-MMP).

Authors:  Lingyun Mou; Yawei Kang; Ying Zhou; Qian Zeng; Hongjing Song; Rui Wang
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

3.  Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes.

Authors:  Chang-Jiang Guo; Steven D Douglas; Zhiyong Gao; Bryan A Wolf; Judith Grinspan; Jian-Ping Lai; Eric Riedel; Wen-Zhe Ho
Journal:  Glia       Date:  2004-11-15       Impact factor: 7.452

4.  Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.

Authors:  C Palma; M Bigioni; C Irrissuto; F Nardelli; C A Maggi; S Manzini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

5.  Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.

Authors:  Christine Rangger; Anna Helbok; Jane Sosabowski; Christian Kremser; Gottfried Koehler; Ruth Prassl; Fritz Andreae; Irene J Virgolini; Elisabeth von Guggenberg; Clemens Decristoforo
Journal:  Int J Nanomedicine       Date:  2013-12-05

6.  The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.

Authors:  Mario F Muñoz; Sandro Argüelles; Marisa Rosso; Rafael Medina; Rafael Coveñas; Antonio Ayala; Miguel Muñoz
Journal:  Biomed Res Int       Date:  2022-04-04       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.